List of Gene Therapy Companies in Georgia - 8

AMD Biotech, Inc. was founded with a prime focus on the development of nano-magnetic bead technology and its capabilities. Through in-depth research and development, AMD Biotech, Inc. has established the unique technology and production system of nano-magnetic particles for array of products.

Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Dogwood is pioneering Halneuron®, a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer pain, and other pain indications. It is also developing the antiviral combination therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”)

Emory University is an academic institution that offers a wide range of undergraduate, graduate, and research programs.

Expression Therapeutics, Inc. is a fully integrated clinical stage gene and cell therapy company developing novel, potentially curative, therapeutics for hematology and oncology. The Company, based in Atlanta, Georgia, has a state-of-the-art 43,000 square foot manufacturing facility in West Chester, Ohio. Expression Therapeutics, Inc. also built a state-of-the-art scalable 43,000 square foot manufacturing facility in Cincinnati, Ohio.

GeneCure Biotechnologies is a biotechnology company that focuses on developing gene therapy based technologies to treat genetic and acquired human diseases.

Slingshot Biosciences is working on an overlooked but ubiquitous problem in healthcare that has a tremendous impact on a variety of patient outcomes: the lack of consistent reference material for cell-based assays. The company’s cell mimics represent a new way to use control material in the workflow, whether for instrument manufacturing, assay setup, and validation or as a manufacturing QC control. Synthetic cell mimics provide a new opportunity for precise, biologically-relevant, and cost-effective controls to aid many healthcare and research efforts globally. Learn more at slingshotbio.com